Premium
Determination of response to taxol/carboplatin in ovarian cancer patients
Author(s) -
Frudakis T. N.,
Thomas M.,
Gaskin Z.,
Gomez H. J.
Publication year - 2005
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/j.clpt.2004.12.124
Subject(s) - carboplatin , biology , single nucleotide polymorphism , haplotype , confounding , genome , genome wide association study , genetics , computational biology , gene , snp , population , pharmacogenomics , 1000 genomes project , medicine , cisplatin , allele , genotype , chemotherapy , environmental health
Background We deal with genetic complexity through population structure to reduce the number of markers, condition case/control study results and combat the confounding influence of genetic heterogeneity and minor locus effects. This abstract describes the screening of patient genomes to construct a DNA based test for measuring Taxol/Carboplatin response proclivities. Methods Pan genome maps of Ancestry Informative Markers to estimate individual biogeographical ancestry admixture for patient samples, integrated with a case/control design were used to screen the genome. Results Taxol/Carboplatin response was associated with Haplotypes in 3 xenobiotic metabolism genes and a few other SNPs. Integrating ancestry and gene‐specific features enabled construction of a classification method for predicting Taxol/Carboplatin response proclivities that is capable of relatively sensitive, specific and powerful performance in “blind” sample classification trials. Conclusions When gene haplotype and SNP associations are viewed through the lens of biogeographical ancestry admixture, pattern emerges that enables relatively accurate classification of patient response proclivities to Taxol/Carboplatin in ovarian cancer patients. Clinical Pharmacology & Therapeutics (2005) 77 , P61–P61; doi: 10.1016/j.clpt.2004.12.124